English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Guillain-Barré syndrome (GBS) presents as acute inflammatory demyelinating polyneuropathy, which leads to rapid-onset muscle weakness classically caused by immune-mediated damage to the peripheral nervous system. We report here a case of GBS occurring during treatment with nivolumab. Nivolumab is a fully human IgG4 programmed death 1 (PD-1) immune-checkpointinhibitor antibody that selectively blocks the interaction of the PD-1 receptor with its 2 known programmed death ligands, PD-L1 and PD-L2. Nivolumab can thereby restore anticancer immune responses by abrogating PD-1 pathway-mediated T-cell inhibition (1). In addition, we discuss possible underlying disease mechanisms and treatment options.

PD-1 Antibody-induced Guillain-Barré Syndrome in a Patient with Metastatic Melanoma